Literature DB >> 28273699

[Use of noninvasive high-frequency oscillatory ventilation in very low birth weight infants].

C H Wang1, L P Shi, X L Ma, H J Lin, Y P Xu, L Z Du.   

Abstract

Objective: To evaluate the effectiveness and safety of the use of noninvasive high-frequency oscillation ventilation (nHFOV) in very low birth weight infants. Method: A total of 36 cases received nHFOV between January 2016 and October 2016 in Children's Hospital, Zhejiang University School of Medicine, including 24 males and 12 females, with the gestational age of (27.5±2.5) weeks and birth weight of(980±318)g. The data of the ventilator settings, side effects, and changes of the respiratory function before and after nHFOV were collected and analyzed retrospectively. Nonparametric tests or t tests or χ(2) tests were used. Result: Thirty-two (89%) out of the 36 cases successfully avoided intubation or re-intubation after using of nHFOV. nHFOV was used as the rescue treatment after failure of other noninvasive ventilation in 17 cases, and as the prophylactical treatment preventing re-intubation after extubation in the remaining 19 cases. There were significant decreases in the incidences of apnea and desaturation(SpO(2)<0.85), the level of PaCO(2, )and the FiO(2) 24 h after the initiation of the nHFOV as the rescue therapy((1.2±1.1)vs.(6.3±2.1)episodes , (1.1±1.2) vs.(4.3±1.5) episodes, (43±8) vs.(56±10) mmHg, 0.30±0.07 vs. 0.39±0.11, respectively; 1 mmHg=0.133 kPa, t=7.562, 8.913, 4.179, 3.437 respectively, all P<0.01). No significant changes were found in FiO(2) and PaCO(2) levels 24 h after initiation of nHFOV as the prophylactical therapy after extubation (0.42±0.12 vs.0.40±0.10, (49±8)vs.(48±7)mmHg, t=0.872 and 0.501 respectively, both P>0.05), except for the significant decreases in the mean airway pressure ((7.9±2.6)vs.(9.6±1.6)cmH(2)O, 1 cmH(2)0=0.098 kPa, t=2.198, P=0.041). There were 4 cases suffered from nasal septum injury, while no other nHFOV related complications were noted.
Conclusion: nHFOV can be applied in preterm infants as a rescue treatment after the failure of other noninvasive ventilation, or prophylactically used in patients who have high risk of re-intubation.

Entities:  

Keywords:  Bronchopulmonary dysplasia; High-frequency ventilation; Infant, very low birth weight; Noninvasive ventilation

Mesh:

Year:  2017        PMID: 28273699     DOI: 10.3760/cma.j.issn.0578-1310.2017.03.003

Source DB:  PubMed          Journal:  Zhonghua Er Ke Za Zhi        ISSN: 0578-1310


  5 in total

1.  Evaluation of three non-invasive ventilation modes after extubation in the treatment of preterm infants with severe respiratory distress syndrome.

Authors:  Gaole Yuan; Hailan Liu; Zhihong Wu; Xiao Chen
Journal:  J Perinatol       Date:  2022-08-11       Impact factor: 3.225

2.  Noninvasive high-frequency oscillatory ventilation versus bi-level positive pressure ventilation in premature infants with respiratory failure: A retrospective study.

Authors:  Wenqian Chen; Zhiqing Chen; Shuhua Lai; Wenhong Cai; Yunfeng Lin
Journal:  Pak J Med Sci       Date:  2022 May-Jun       Impact factor: 2.340

3.  Three non-invasive ventilation strategies for preterm infants with respiratory distress syndrome: a propensity score analysis.

Authors:  Huiling Cao; Huanhuan Li; Xingwang Zhu; Li Wang; Ming Yi; Chuanfeng Li; Long Chen; Yuan Shi
Journal:  Arch Med Sci       Date:  2020-03-09       Impact factor: 3.318

4.  Non-invasive high-frequency oscillatory ventilation in preterm infants after extubation: a randomized, controlled trial.

Authors:  Yan Li; Qiufen Wei; Dan Zhao; Yan Mo; Liping Yao; Lingxiao Li; Wei Tan; Xinnian Pan; Jiayan Yao; Wei Dai; Danni Zhong
Journal:  J Int Med Res       Date:  2021-02       Impact factor: 1.671

5.  Non-invasive high-frequency oscillatory ventilation versus nasal continuous positive airway pressure in preterm infants with respiratory distress syndrome: Study protocol for a multi-center prospective randomized controlled trial.

Authors:  Xing-Wang Zhu; Yuan Shi; Li-Ping Shi; Ling Liu; Jiang Xue; Rangasamy Ramanathan
Journal:  Trials       Date:  2018-06-14       Impact factor: 2.279

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.